
Validea's guru fundamental report rated MEDTRONIC PLC (MDT) at 69% using the Martin Zweig Growth Investor model, placing it below the 80% threshold typically indicating 'some interest' by this strategy. While the large-cap Medical Equipment & Supplies firm passed several current growth and valuation metrics, it notably failed on key criteria such as earnings persistence and long-term EPS growth, suggesting it does not fully align with a strategy seeking consistent, accelerating growth.
Based on Validea's Martin Zweig Growth Investor model, Medtronic PLC (MDT) receives a score of 69%, falling below the 80% threshold that typically indicates strategic interest. The analysis reveals a distinct dichotomy in the company's fundamentals: while MDT passes several key criteria related to its current state, it fails on crucial long-term growth and consistency metrics. Positively, the company meets the model's standards for its P/E ratio, sales growth rate, low total debt/equity, and positive insider transactions. Furthermore, it shows strong near-term momentum, passing tests for current quarter earnings growth, which is accelerating faster than both the prior three quarters and its historical rate. However, these strengths are offset by significant weaknesses, as MDT fails the tests for 'Earnings Persistence,' 'Long-Term EPS Growth,' and 'Earnings Growth Rate for the past several quarters.' This mixed result suggests a company experiencing a recent positive inflection in performance but lacking the proven track record of sustained, accelerating growth that is a hallmark of the Zweig strategy.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request a DemoOverall Sentiment
mixed
Sentiment Score
-0.10
Ticker Sentiment